TIAP portfolio company Zucara Therapeutics moves their lead program targeting diabetes into Phase II clinical trials. Read more here.

Why this news is important:

• Zucara has achieved the development milestones required to secure the remaining funds available from its previously announcedUS$21 million Series A Financing.
• Zucara plans to file an investigational new drug (“IND”) application for a Phase 2 trial by year end, with initiation of first patient dosing expected in Q1 2023.
• ZT-01 has the potential to become the first therapeutic designed to prevent hypoglycemia in people with Type 1 diabetes.